TEVA - Why Long-Term Investors Should Avoid TEVA Stock Like the Plague
Israeli company Teva Pharmaceuticals (NYSE: TEVA) has been a leader in the healthcare industry for more than 40 years with offerings ranging from generics to specialty drugs like neurodegenerative and oncological medicines to groundbreaking biosimilars. Teva is the single largest producer of generic medicines across the globe, with a company footprint that extends to over 60 countries.
But Teva's days as the pharmaceutical golden child could be waning.
Teva stock has experienced a massive decline over the past few years, and ongoing debt issues continue to weigh the company down. Not only that, but Teva has faced an onslaught of legal actions ranging from opioid scandals to a recent whistleblower lawsuit -- and at the time of this article, the litigation debacle rages on.